CN100387716C - Preparation of KTV series products for inhibiting tumor cell growth and use - Google Patents
Preparation of KTV series products for inhibiting tumor cell growth and use Download PDFInfo
- Publication number
- CN100387716C CN100387716C CNB2004100622966A CN200410062296A CN100387716C CN 100387716 C CN100387716 C CN 100387716C CN B2004100622966 A CNB2004100622966 A CN B2004100622966A CN 200410062296 A CN200410062296 A CN 200410062296A CN 100387716 C CN100387716 C CN 100387716C
- Authority
- CN
- China
- Prior art keywords
- leu
- ser
- glu
- lys
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 7
- 230000002401 inhibitory effect Effects 0.000 title abstract 4
- 230000004565 tumor cell growth Effects 0.000 title 1
- 241000700605 Viruses Species 0.000 claims abstract description 59
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 30
- 241000238631 Hexapoda Species 0.000 claims abstract description 25
- 241000701447 unidentified baculovirus Species 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 46
- 241000701161 unidentified adenovirus Species 0.000 claims description 34
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 32
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 20
- 230000012010 growth Effects 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 206010027476 Metastases Diseases 0.000 claims description 13
- 230000009401 metastasis Effects 0.000 claims description 13
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 claims description 11
- 241000701409 Lymantria dispar multiple nucleopolyhedrovirus Species 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 238000010369 molecular cloning Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 102000057593 human F8 Human genes 0.000 claims 2
- 229940047431 recombinate Drugs 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 47
- 241000282414 Homo sapiens Species 0.000 abstract description 17
- 230000004614 tumor growth Effects 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 7
- 238000010276 construction Methods 0.000 abstract description 4
- 241000598171 Human adenovirus sp. Species 0.000 abstract description 2
- 239000000969 carrier Substances 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 101000621041 Homo sapiens Retinoblastoma-like protein 2 Proteins 0.000 description 35
- 102100022828 Retinoblastoma-like protein 2 Human genes 0.000 description 26
- 101001062114 Zea mays Retinoblastoma-related protein 1 Proteins 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 241000701022 Cytomegalovirus Species 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 102220023257 rs387907546 Human genes 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- 102220023256 rs387907547 Human genes 0.000 description 8
- 102220369447 c.1352G>A Human genes 0.000 description 7
- 238000013016 damping Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 108700025694 p53 Genes Proteins 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000721703 Lymantria dispar Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101150002130 Rb1 gene Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 102220023258 rs387907548 Human genes 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 3
- 108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 3
- 108700025695 Suppressor Genes Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 102220369445 c.668T>C Human genes 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 102220004457 rs11567847 Human genes 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- AZUVBPVDRHGGEP-UHFFFAOYSA-N 6a,9a-dimethyl-4,5,7,8,9,9a-hexahydro-6aH-dipyrrolo(2,3-b;3',2',1'-hi)indole Natural products CC(=C)C1CCC(C)=CCCC(C)=CCCC(C)=CC1O AZUVBPVDRHGGEP-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 241001367049 Autographa Species 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 2
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 101710109576 Terminal protein Proteins 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 102220369446 c.1274G>A Human genes 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- KHWTYGFHPHRQMP-UHFFFAOYSA-N (4-propan-2-ylcyclohexyl)methanol Chemical compound CC(C)C1CCC(CO)CC1 KHWTYGFHPHRQMP-UHFFFAOYSA-N 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108010037936 CCCGGG-specific type II deoxyribonucleases Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 102100031561 Hamartin Human genes 0.000 description 1
- 101710175981 Hamartin Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 101000620814 Homo sapiens Ras and EF-hand domain-containing protein Proteins 0.000 description 1
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 description 1
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 101710124584 Probable DNA-binding protein Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100022869 Ras and EF-hand domain-containing protein Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108010003494 Retinoblastoma-Like Protein p130 Proteins 0.000 description 1
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- -1 p16 Proteins 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241000701451 unidentified granulovirus Species 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100622966A CN100387716C (en) | 2004-07-05 | 2004-07-05 | Preparation of KTV series products for inhibiting tumor cell growth and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100622966A CN100387716C (en) | 2004-07-05 | 2004-07-05 | Preparation of KTV series products for inhibiting tumor cell growth and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1587411A CN1587411A (en) | 2005-03-02 |
CN100387716C true CN100387716C (en) | 2008-05-14 |
Family
ID=34603682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100622966A Expired - Lifetime CN100387716C (en) | 2004-07-05 | 2004-07-05 | Preparation of KTV series products for inhibiting tumor cell growth and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100387716C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105986007B (en) * | 2015-02-11 | 2020-03-17 | 深圳华大基因股份有限公司 | Detection method of cancer tumor suppressor gene cluster (TSG) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1242051A (en) * | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | Cytopathic virus for the treatment and prevention of tumors |
US6814963B2 (en) * | 2001-03-23 | 2004-11-09 | National Health Research Institutes | Baculovirus-based expression system |
-
2004
- 2004-07-05 CN CNB2004100622966A patent/CN100387716C/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1242051A (en) * | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | Cytopathic virus for the treatment and prevention of tumors |
US6814963B2 (en) * | 2001-03-23 | 2004-11-09 | National Health Research Institutes | Baculovirus-based expression system |
Non-Patent Citations (4)
Title |
---|
RB-mediated suppression of spontaneous multipleneuroendocrine neoplasia and lung metastases in Rb+/- mice. ALEXANDER YU. et al.Proc. Natl. Acad. Sci. USA,Vol.96 . 1999 |
RB-mediated suppression of spontaneous multipleneuroendocrine neoplasia and lung metastases in Rb+/- mice. ALEXANDER YU. et al.Proc. Natl. Acad. Sci. USA,Vol.96 . 1999 * |
肿瘤抑制基因在恶性肿瘤基因治疗中的应用. 吴焱等.国外医学遗传学分册,第24卷第1期. 2001 |
肿瘤抑制基因在恶性肿瘤基因治疗中的应用. 吴焱等.国外医学遗传学分册,第24卷第1期. 2001 * |
Also Published As
Publication number | Publication date |
---|---|
CN1587411A (en) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110128550B (en) | Novel replicative oncolytic adenovirus capable of simultaneously blocking immune check points PD-L1 and TIGIT and application | |
Cao et al. | Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity | |
US6432927B1 (en) | Compositions and methods for inducing gene expression | |
JP4434479B2 (en) | Nucleic acid sequences and methods for selectively expressing proteins in target cells and tissues | |
WO2011062298A1 (en) | System for increasing gene expression, and vector supporting said system | |
CA2158655A1 (en) | Process for preparing cancer vaccines | |
CN111606999B (en) | Replicative oncolytic adenovirus with functions of activating immune co-stimulatory signaling pathway and blocking immune checkpoint and application thereof | |
Yamamura et al. | Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors | |
CN110393791A (en) | The anti-infectious function of hnRNPA2B1 and its application | |
CN110423812B (en) | Use of Skiv2l2 (MTR 4) gene in tumor treatment | |
CN100387716C (en) | Preparation of KTV series products for inhibiting tumor cell growth and use | |
US20050025754A1 (en) | Increased T-cell tumor infiltration by mutant light | |
Yamada et al. | Retrovirus‐mediated gene transfer targeted to malignant glioma cells in murine brain | |
Aframian et al. | Using HSV-thymidine kinase for safety in an allogeneic salivary graft cell line | |
US20220154149A1 (en) | Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics | |
CN113373176A (en) | Construction method of gene therapy vector and application of gene therapy vector in Alzheimer disease drugs | |
Sutkowski et al. | A murine model for B-lymphocyte somatic cell gene therapy. | |
CN101219222B (en) | Application of PDCD4 recombined expression vector in preparing medicament for treating gonad cancer | |
Eslahi et al. | Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy | |
CN101302256A (en) | Novel recombinant fusion molecule and antineoplastic treatment function thereof | |
WO2024167300A1 (en) | Anti-cancer salmonella strain that induces tumor cell necrosis, and anti-cancer composition comprising same | |
US20070036787A1 (en) | Insulin-induced gene as therapeutic target in diabetes | |
JP2003500336A (en) | Use of apoptosis inducers in the treatment of (auto) immune diseases | |
WO2020171269A1 (en) | Prc1 promoter for regulating cancer cell-specific gene expression and recombinant vector containing same | |
CN112430577A (en) | Chimeric antigen receptor T cell targeting EGFRv III and interfering IL-6 expression, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN BOYING BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: YU ZAILIN; APPLICANT Effective date: 20070216 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070216 Address after: 300457, Tianjin TEDA economic and Technological Development Zone, international entrepreneurship center, 10 floor Applicant after: TIANJIN SINOBIOTECH LTD. Address before: 100028 Beijing city Chaoyang District Henan Road No. 3 Haohongyuan house 19-A Applicant before: Yu Zailin Co-applicant before: Fu Yan |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: TIANJIN GREENBIO MATERIAL Co.,Ltd. Assignor: TIANJIN SINOBIOTECH LTD. Contract record no.: 2010120000059 Denomination of invention: Preparation of KTV series products for inhibiting tumor cell growth and use Granted publication date: 20080514 License type: Exclusive License Open date: 20050302 Record date: 20100512 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: TIANJIN GREENBIO MATERIAL Co.,Ltd. Assignor: TIANJIN SINOBIOTECH LTD. Contract record no.: 2010120000059 Date of cancellation: 20100903 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: BEIJING MEIFUYUAN BIOMEDICAL TECHNOLOGY CO.,LTD. Assignor: TIANJIN SINOBIOTECH LTD. Contract record no.: 2011990000408 Denomination of invention: Preparation of KTV series products for inhibiting tumor cell growth and use Granted publication date: 20080514 License type: Exclusive License Open date: 20050302 Record date: 20110531 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20231211 Address after: Unit 1601, 13th Floor, Building 15, Xiaguangli, Chaoyang District, Beijing, 100000 Patentee after: Fortune Rock (China) Co.,Ltd. Address before: 300457, Tianjin TEDA economic and Technological Development Zone, international entrepreneurship center, 10 floor Patentee before: TIANJIN SINOBIOTECH LTD. |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20080514 |